Article
Oncology
Shengchen Su, Sungyong You, Yanping Wang, Patrick Tamukong, Michael J. Quist, Catherine S. Grasso, Hyung L. Kim
Summary: Antitumor immunity requires lymphocytes to localize to the tumor. Prostate cancers (PCs) are immunologically cold and tend to lack T-cell infiltration. Most advanced PCs are insensitive to PD1 blockade therapies.
Article
Oncology
Angela Tata, Garvin Dodard, Celine Fugere, Corinne Leget, Melody Ors, Benjamin Rossi, Eric Vivier, Laurent Brossay
Summary: Blocking KLRG1 enhances anti-tumor immunity mediated by NK cells and CD8(+) T cells, and synergizes with PD-1 checkpoint therapy to significantly decrease tumor growth. Double blockade therapy leads to decreased tumor size, increased frequency and activation of T cells and NK cells in the tumor microenvironment.
Article
Cell & Tissue Engineering
Hao Yu, Yan Liu, Xiangwen Yang, Jiajing He, Fan Zhang, Qun Zhong, Xiaojing Guo
Summary: Strontium ranelate can promote BMSCs chondrogenic differentiation by inhibiting the Wnt/beta-catenin signaling pathway and accelerate cartilage regeneration in rat femoral condyle defects.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Chemistry, Multidisciplinary
Xiaowei Liu, Yanlin Feng, Jie Xu, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang, Hubing Shi
Summary: The research demonstrates the advantage of photothermal-targeted-immune triple combinatorial regimen in treating tumors that are clinically unresectable multifocal and lack T-cell infiltration.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Kazuya Nishii, Kadoaki Ohashi, Shuta Tomida, Takamasa Nakasuka, Atsuko Hirabae, Sachi Okawa, Jun Nishimura, Hisao Higo, Hiromi Watanabe, Hirohisa Kano, Chihiro Ando, Go Makimoto, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Shinichi Toyooka, Heiichiro Udono, Yoshinobu Maeda, Katsuyuki Kiura
Summary: EGFR-mutant NSCLC has a noninflamed tumor microenvironment with weak response to immune-checkpoint inhibitors. EGFR-tyrosine kinase inhibitor can induce CD8+ T-cell responses, which are further enhanced by the dual blockade of PD-1 and VEGFR2. These findings could aid in developing alternative immunotherapy strategies for patients with driver mutations and a noninflamed tumor microenvironment.
CANCER IMMUNOLOGY RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir
Summary: Immune checkpoint inhibitors have shown promise in cancer treatment but are not always long-lasting and effective for all patients. Targeting TAM kinases with tyrosine kinase inhibitors may enhance the efficacy of immune checkpoint blockade, but whether selective targeting of each TAM receptor or multi-receptor TAM inhibitors are more effective remains to be determined. Triple inhibition of all TAM receptors may lead to increased risk of adverse events, and clinical trial designs should focus on determining the synergistic effects of combining TAM inhibition with immune checkpoint blockade through high-resolution clinical endpoints and proper control arms.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2021)
Article
Oncology
Qian Wu, Yi-Fei Xuan, Ai-Ling Su, Xu-Bin Bao, Ze-Hong Miao, Ying-Qing Wang
Summary: The combination of BET inhibitors and TNK inhibitors has been found to effectively inhibit the proliferation and induce apoptosis of colorectal cancer cells. This combination treatment can suppress beta-Catenin accumulation through multiple molecular mechanisms and has a synergistic effect on G1 cell cycle arrest and decreased colony-forming ability.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Han Chu, Zheng Jin, Jia-nan Cheng, Qingzhu Jia, Bo Zhu, Haoyang Cai
Summary: In this study, the association among chromothripsis, anti-tumor immune responses, and responsiveness to immune checkpoint blockade (ICB) was investigated. It was found that tumors with chromothripsis had reduced cytotoxic immune infiltration and enhanced immunosuppression in the tumor microenvironment. Chromothripsis can be used as an independent predictor for the responsiveness to ICB.
Article
Environmental Sciences
Han Song, Junjun Qiu, Keqin Hua
Summary: USP14 is overexpressed in cervical cancer and is associated with clinical stage and prognosis of patients. It promotes the proliferation, migration, and invasion of cervical cancer cells by upregulating the expression of beta-catenin.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Zili Gu, Candido G. Da Silva, Yang Hao, Timo Schomann, Marcel G. M. Camps, K. van der Maaden, Qi Liu, Ferry Ossendorp, Luis J. Cruz
Summary: Therapeutic cancer drug efficacy is often limited by factors such as insufficient tumor penetration, rapid clearance, systemic toxicity, and drug resistance. In this study, a liposomal platform was used to improve the therapeutic index by enhancing drug penetration and reducing clearance and toxicity. The combination of docetaxel and pemetrexed encapsulated in pH-sensitive liposomes showed strong cytotoxicity and induced immunogenic cell death in cellular experiments. In vivo, the liposome-based drug combination inhibited tumor development and stimulated immune responses, with significantly reduced systemic toxicity. When combined with anti-PD-L1 immunotherapy, tumor control was further enhanced in mouse models of colon cancer. These findings highlight the promising potential of liposome-mediated chemotherapy combined with immunotherapy for the treatment of colon cancers.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Naoki Okada, Ko Sugiyama, Shunsuke Shichi, Yasuhito Shirai, Kaoru Goto, Fumio Sakane, Hidemitsu Kitamura, Akinobu Taketomi
Summary: Inhibition of DGK alpha shows promise as a novel therapeutic strategy for hepatocellular carcinoma by suppressing tumor growth and enhancing host immune responses.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Ombretta Melaiu, Gianluca Vanni, Ilaria Portarena, Chiara Adriana Pistolese, Lucia Anemona, Silvia Pomella, Roberto Bei, Oreste Claudio Buonomo, Mario Roselli, Alessandro Mauriello, Giovanni Barillari
Summary: Immune checkpoint inhibitors have limited clinical activity as monotherapy against breast cancer, and novel combinatorial strategies are being investigated to improve treatment response. The abnormal vasculature in breast cancer is associated with immune suppression and hampers drug delivery and immune cell trafficking. Combining immune checkpoint inhibitors with tumor vessel normalizing agents shows promise in enhancing antitumor immune responses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Rui Wang, Tao Zhang, Yuan Lu, Yalong Lin, Shuyuan Kou, Xuefeng Li, Yang Wang, Liangzhi Xie
Summary: This study evaluated the utilization of pegylated human interferon beta (PEG-IFN beta) in antitumor therapy and found that it showed superior tumor growth inhibitory and dendritic cell-activating activities compared to pegylated interferon alpha. The findings suggest that using PEG-IFN beta can enhance the therapeutic effect of immune checkpoint inhibitors in resistant tumors.
CELLULAR IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Mianmian Liao, Caiwei Wang, Bowen Yang, Danping Huang, Yifeng Zheng, Shengqi Wang, Xuan Wang, Juping Zhang, Chunbian Tang, Zheng Xu, Yu He, Ruolin Huang, Fengxue Zhang, Zhiyu Wang, Neng Wang
Summary: Accumulating evidence suggests that the mechanism of chemosensitization by ADQ in breast CSCs involves regulating autophagy, reducing the breast CSC population, and blocking autophagy through beta-catenin/ABCG2 signaling. The study also highlights the role of GRP78 in mediating autophagy-related drug resistance and the chemosensitizing effects of ADQ in breast cancer cells.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yuting Tang, Qian Xu, Liang Hu, Xiaomei Yan, Xiaomin Feng, Asumi Yokota, Weinan Wang, Di Zhan, Durga Krishnamurthy, David E. Ochayon, Lijun Wen, Li Huo, Huimin Zeng, Yingwan Luo, Mark Wunderlich, Jiwang Zhang, Eric Vivier, Jianfeng Zhou, Stephen N. Waggoner, Gang Huang
Summary: R-spondin 3 expression is associated with favorable prognosis and enhances infiltration and function of NK cells and T cells in tumors, leading to tumor regression, and also increases tumor sensitivity to anti-PD-1 therapy.